성장인자 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Persistence Market Research has recently released a comprehensive report on the global Growth Factors Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions

Key Insights:

• Growth Factors Market Size (2024E): US$ 2.2 Bn
• Projected Market Value (2031F): US$ 3.3 Bn
• Global Market Growth Rate (CAGR 2024 to 2031): 5.8%

Growth Factors Market - Report Scope:

The global growth factors market comprises biologically active proteins or peptides that play essential roles in cell proliferation, differentiation, and tissue regeneration. These compounds are increasingly being used in regenerative medicine, oncology, and chronic disease management. The market's growth trajectory is influenced by innovations in biotechnology, enabling the production of recombinant growth factors with enhanced efficacy and scalability. The market also benefits from supportive government initiatives, rising investments in biomedical research, and the increasing prevalence of chronic diseases worldwide.

Market Drivers:

The growth factors market is primarily driven by the rising prevalence of chronic diseases such as cancer and diabetes, necessitating advanced therapeutic solutions. Growth factors play a pivotal role in targeted therapies and regenerative medicine, further driving their adoption in tissue engineering and wound healing applications. Technological advancements in biotechnology have revolutionized the production of recombinant growth factors, enhancing their accessibility and effectiveness. Additionally, the global aging population is creating a surge in demand for innovative therapeutic approaches. Government initiatives and increased funding for biomedical research provide further impetus to the market, while advancements in personalized medicine amplify the potential of growth factors in precision therapies.

Market Restraints:

Despite the favorable growth prospects, the global growth factors market faces several challenges. The high costs associated with the production and commercialization of recombinant growth factors can hinder their widespread adoption, particularly in cost-sensitive markets. Regulatory hurdles and stringent approval processes can delay product launches, impacting market growth. Furthermore, limited awareness about the therapeutic applications of growth factors in developing regions and competition from alternative treatment modalities pose additional challenges for the market.

Market Opportunities:

Significant growth opportunities exist in the development of novel applications for growth factors in regenerative medicine and chronic disease management. The expansion of growth factors into emerging fields such as oncology and personalized medicine opens up new avenues for innovation. Collaborative efforts between biotechnology firms, research institutions, and healthcare providers are expected to accelerate advancements in this domain. Moreover, the increasing adoption of precision medicine presents substantial market potential, particularly in developed regions with advanced healthcare infrastructure. Untapped markets in emerging economies, supported by growing healthcare investments, represent another promising growth area for the market.

Key Questions Answered in the Report:

• What are the primary factors driving the global growth of the growth factors market?
• Which therapeutic areas are gaining the highest adoption across different regions?
• How are advancements in biotechnology shaping the competitive landscape of the growth factors market?
• Who are the key players in the growth factors market, and what strategies are they employing to maintain their market positions?
• What are the emerging trends and future outlooks for the global growth factors market?

Competitive Intelligence and Business Strategy:

Leading companies in the global growth factors market, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Merck KGaA, and Lonza Group AG, are focusing on innovations in biotechnology to maintain their competitive edge. These players are leveraging advancements in recombinant technology to develop highly efficacious growth factors for targeted therapies and regenerative applications. Partnerships between pharmaceutical companies and academic research institutions are driving research and accelerating commercialization timelines. Companies are also emphasizing affordability and accessibility to cater to a broader patient population while aligning with global healthcare goals.

Key Companies Profiled:

• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• Lonza Group AG
• F. Hoffmann-La Roche Ltd.
• Sartorius CellGenix GmbH
• Bio-Techne Corporation
• GenScript
• Miltenyi Biotec.
• Abcam PLC
• Sino Biological Inc.
• Cell Signaling Technology, Inc.
• ACROBiosystems
• Becton, Dickinson, and Company
• Creative Bioarray
• Applied Biological Materials (abm) Inc.
• GE Healthcare
• Meridian Bioscience Inc.
• Repligen Corporation
• Aviva Systems Biology Corporation (GenWay Biotech)
• Leadgene Biomedical, Inc.
• Boster Bio
• Prospec-Tany Technogene Ltd.
• Proteintech Group, Inc.
• AJINOMOTO CO., Inc.
• STEMCELL Technologies
• Akron Biotech
• PeproTech Inc.

Growth Factors Market Segmentation:

By Product

• Transforming Growth Factors (TGF)
• Epidermal Growth Factors (EGFs)
• Platelet-derived Growth Factors (PDGFs)
• Fibroblast Growth Factors (FGFs)
• Insulin-like Growth Factors (IGFs)
• Vascular Endothelial Growth Factors (VEGFs)
• Hepatocyte Growth Factors (HGFs)
• Tumor Necrosis Factors (TNFs)
• Interleukins
• Others

By Grade

• GMP Grade
• NON-GMP Grade

By Application

• Oncology
• Hematology
• Wound Healing
• Dermatology
• Cardiovascular Disease and Diabetes
• Cell Therapy and EX-vivo Manufacturing
• Others

By Expression Host System

• Animal-derived
• Recombinant

By Mode of Action

• Angiogenic
• Anti-apoptotic
• Mitogenic

By Species Origin

• Human
• Pig
• Mouse
• Rat
• Others

By End User

• Pharmaceutical and Biotechnology Companies
• Research Centers and Academic Institutes
• Contract Research Organizations

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Growth Factors Market Snapshot, 2024 and 2031
• 1.2. Market Opportunity Assessment, 2024 - 2031, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Product Adoption Analysis
• 3.3. Value Chain Analysis
• 3.4. Key Deals and Mergers
• 3.5. PESTLE Analysis
• 3.6. Porter's Five Force Analysis

4. Global Growth Factors Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2023
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024 - 2031
• 4.3. Global Growth Factors Market Outlook: Product
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product, 2019 - 2023
  • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2023 - 2031
    • 4.3.3.1. Transforming Growth Factors (TGF)
      • 4.3.3.1.1. Activin
      • 4.3.3.1.2. Bone Morphogenetic Proteins (BMPs)
      • 4.3.3.1.3. TGF-beta Proteins
    • 4.3.3.2. Epidermal Growth Factors (EGFs)
    • 4.3.3.3. Platelet-Derived Growth Factors (PDGFs)
    • 4.3.3.4. Fibroblast Growth Factors (FGFs)
    • 4.3.3.5. Insulin-like Growth Factors (IGFs)
    • 4.3.3.6. Vascular Endothelial Growth Factors (VEGFs)
    • 4.3.3.7. Hepatocyte Growth Factors (HGFs)
    • 4.3.3.8. Tumor Necrosis Factors (TNFs)
    • 4.3.3.9. Interleukins
    • 4.3.3.10. Others
  • 4.3.4. Market Attractiveness Analysis: Product
• 4.4. Global Growth Factors Market Outlook: Grade
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Grade, 2019 - 2023
  • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Grade, 2023 - 2031
    • 4.4.3.1. GMP Grade
    • 4.4.3.2. NON-GMP Grade
  • 4.4.4. Market Attractiveness Analysis: Grade
• 4.5. Global Growth Factors Market Outlook: Application
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019 - 2023
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2023 - 2031
    • 4.5.3.1. Oncology
    • 4.5.3.2. Hematology
    • 4.5.3.3. Wound Healing
    • 4.5.3.4. Dermatology
    • 4.5.3.5. Cardiovascular Disease & Diabetes
    • 4.5.3.6. Cell Therapy & EX-vivo Manufacturing
    • 4.5.3.7. Others
  • 4.5.4. Market Attractiveness Analysis: Application
• 4.6. Global Growth Factors Market Outlook: Expression Host System
  • 4.6.1. Introduction / Key Findings
  • 4.6.2. Historical Market Size (US$ Bn) Analysis, By Expression Host System, 2019 - 2023
  • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Expression Host System, 2023 - 2031
    • 4.6.3.1. Animal Derived
    • 4.6.3.2. Recombinant
  • 4.6.4. Market Attractiveness Analysis: Expression Host System
• 4.7. Global Growth Factors Market Outlook: Mode of Action
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Bn) Analysis, By Mode of Action, 2019 - 2023
  • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Mode of Action, 2023 - 2031
    • 4.7.3.1. Angiogenic
    • 4.7.3.2. Anti-apoptotic
    • 4.7.3.3. Mitogenic
  • 4.7.4. Market Attractiveness Analysis: Mode of Action
• 4.8. Global Growth Factors Market Outlook: Species Origin
  • 4.8.1. Introduction / Key Findings
  • 4.8.2. Historical Market Size (US$ Bn) Analysis, By Species Origin, 2019 - 2023
  • 4.8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Species Origin, 2023 - 2031
    • 4.8.3.1. Human
    • 4.8.3.2. Pig
    • 4.8.3.3. Mouse
    • 4.8.3.4. Rat
    • 4.8.3.5. Others
  • 4.8.4. Market Attractiveness Analysis: Species Origin
• 4.9. Global Growth Factors Market Outlook: End User
  • 4.9.1. Introduction / Key Findings
  • 4.9.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019 - 2023
  • 4.9.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2023 - 2031
    • 4.9.3.1. Pharmaceutical and Biotechnology Companies
    • 4.9.3.2. Research Centers & Academic Institutes
    • 4.9.3.3. Contract Research Organizations
  • 4.9.4. Market Attractiveness Analysis: End User

5. Global Growth Factors Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2023
• 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2023 - 2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Growth Factors Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
  • 6.2.1. By Country
  • 6.2.2. By Product
  • 6.2.3. By Grade
  • 6.2.4. By Application
  • 6.2.5. By Expression Host System
  • 6.2.6. By Mode of Action
  • 6.2.7. By Species Origin
  • 6.2.8. By End User
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2023 - 2031
  • 6.4.1. Transforming Growth Factors (TGF)
    • 6.4.1.1. Activin
    • 6.4.1.2. Bone Morphogenetic Proteins (BMPs)
    • 6.4.1.3. TGF-beta Proteins
  • 6.4.2. Epidermal Growth Factors (EGFs)
  • 6.4.3. Platelet-Derived Growth Factors (PDGFs)
  • 6.4.4. Fibroblast Growth Factors (FGFs)
  • 6.4.5. Insulin-like Growth Factors (IGFs)
  • 6.4.6. Vascular Endothelial Growth Factors (VEGFs)
  • 6.4.7. Hepatocyte Growth Factors (HGFs)
  • 6.4.8. Tumor Necrosis Factors (TNFs)
  • 6.4.9. Interleukins
  • 6.4.10. Others
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Grade, 2023 - 2031
  • 6.5.1. GMP Grade
  • 6.5.2. NON-GMP Grade
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2023 - 2031
  • 6.6.1. Oncology
  • 6.6.2. Hematology
  • 6.6.3. Wound Healing
  • 6.6.4. Dermatology
  • 6.6.5. Cardiovascular Disease & Diabetes
  • 6.6.6. Cell Therapy & EX-vivo Manufacturing
  • 6.6.7. Others
• 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By Expression Host System, 2023 - 2031
  • 6.7.1. Animal-Derived Growth Factors
  • 6.7.2. Recombinant Growth Factors
• 6.8. Current Market Size (US$ Bn) Analysis and Forecast, By Mode of Action, 2023 - 2031
  • 6.8.1. Angiogenic Growth Factors
  • 6.8.2. Anti-Apoptotic Growth Factors
  • 6.8.3. Mitogenic Growth Factors
• 6.9. Current Market Size (US$ Bn) Analysis and Forecast, By Species Origin, 2023 - 2031
  • 6.9.1. Human
  • 6.9.2. Pig
  • 6.9.3. Mouse
  • 6.9.4. Rat
  • 6.9.5. Others
• 6.10. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2023 - 2031
  • 6.10.1. Pharmaceutical and Biotechnology Companies
  • 6.10.2. Research Centers & Academic Institutes
  • 6.10.3. Contract Research Organizations
• 6.11. Market Attractiveness Analysis

7. Europe Growth Factors Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
  • 7.2.1. By Country
  • 7.2.2. By Product
  • 7.2.3. By Grade
  • 7.2.4. By Application
  • 7.2.5. By Expression Host System
  • 7.2.6. By Mode of Action
  • 7.2.7. By Species Origin
  • 7.2.8. By End User
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2023 - 2031
  • 7.4.1. Transforming Growth Factors (TGF)
    • 7.4.1.1. Activin
    • 7.4.1.2. Bone Morphogenetic Proteins (BMPs)
    • 7.4.1.3. TGF-beta Proteins
  • 7.4.2. Epidermal Growth Factors (EGFs)
  • 7.4.3. Platelet-Derived Growth Factors (PDGFs)
  • 7.4.4. Fibroblast Growth Factors (FGFs)
  • 7.4.5. Insulin-like Growth Factors (IGFs)
  • 7.4.6. Vascular Endothelial Growth Factors (VEGFs)
  • 7.4.7. Hepatocyte Growth Factors (HGFs)
  • 7.4.8. Tumor Necrosis Factors (TNFs)
  • 7.4.9. Interleukins
  • 7.4.10. Others
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Grade, 2023 - 2031
  • 7.5.1. GMP Grade
  • 7.5.2. NON-GMP Grade
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2023 - 2031
  • 7.6.1. Oncology
  • 7.6.2. Hematology
  • 7.6.3. Wound Healing
  • 7.6.4. Dermatology
  • 7.6.5. Cardiovascular Disease & Diabetes
  • 7.6.6. Cell Therapy & EX-vivo Manufacturing
  • 7.6.7. Others
• 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By Expression Host System, 2023 - 2031
  • 7.7.1. Animal-Derived Growth Factors
  • 7.7.2. Recombinant Growth Factors
• 7.8. Current Market Size (US$ Bn) Analysis and Forecast, By Mode of Action, 2023 - 2031
  • 7.8.1. Angiogenic Growth Factors
  • 7.8.2. Anti-Apoptotic Growth Factors
  • 7.8.3. Mitogenic Growth Factors
• 7.9. Current Market Size (US$ Bn) Analysis and Forecast, By Species Origin, 2023 - 2031
  • 7.9.1. Human
  • 7.9.2. Pig
  • 7.9.3. Mouse
  • 7.9.4. Rat
  • 7.9.5. Others
• 7.10. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2023 - 2031
  • 7.10.1. Pharmaceutical and Biotechnology Companies
  • 7.10.2. Research Centers & Academic Institutes
  • 7.10.3. Contract Research Organizations
• 7.11. Market Attractiveness Analysis

8. East Asia Growth Factors Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
  • 8.2.1. By Country
  • 8.2.2. By Product
  • 8.2.3. By Grade
  • 8.2.4. By Application
  • 8.2.5. By Expression Host System
  • 8.2.6. By Mode of Action
  • 8.2.7. By Species Origin
  • 8.2.8. By End User
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2023 - 2031
  • 8.4.1. Transforming Growth Factors (TGF)
    • 8.4.1.1. Activin
    • 8.4.1.2. Bone Morphogenetic Proteins (BMPs)
    • 8.4.1.3. TGF-beta Proteins
  • 8.4.2. Epidermal Growth Factors (EGFs)
  • 8.4.3. Platelet-Derived Growth Factors (PDGFs)
  • 8.4.4. Fibroblast Growth Factors (FGFs)
  • 8.4.5. Insulin-like Growth Factors (IGFs)
  • 8.4.6. Vascular Endothelial Growth Factors (VEGFs)
  • 8.4.7. Hepatocyte Growth Factors (HGFs)
  • 8.4.8. Tumor Necrosis Factors (TNFs)
  • 8.4.9. Interleukins
  • 8.4.10. Others
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Grade, 2023 - 2031
  • 8.5.1. GMP Grade
  • 8.5.2. NON-GMP Grade
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2023 - 2031
  • 8.6.1. Oncology
  • 8.6.2. Hematology
  • 8.6.3. Wound Healing
  • 8.6.4. Dermatology
  • 8.6.5. Cardiovascular Disease & Diabetes
  • 8.6.6. Cell Therapy & EX-vivo Manufacturing
  • 8.6.7. Others
• 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By Expression Host System, 2023 - 2031
  • 8.7.1. Animal-Derived Growth Factors
  • 8.7.2. Recombinant Growth Factors
• 8.8. Current Market Size (US$ Bn) Analysis and Forecast, By Mode of Action, 2023 - 2031
  • 8.8.1. Angiogenic Growth Factors
  • 8.8.2. Anti-Apoptotic Growth Factors
  • 8.8.3. Mitogenic Growth Factors
• 8.9. Current Market Size (US$ Bn) Analysis and Forecast, By Species Origin, 2023 - 2031
  • 8.9.1. Human
  • 8.9.2. Pig
  • 8.9.3. Mouse
  • 8.9.4. Rat
  • 8.9.5. Others
• 8.10. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2023 - 2031
  • 8.10.1. Pharmaceutical and Biotechnology Companies
  • 8.10.2. Research Centers & Academic Institutes
  • 8.10.3. Contract Research Organizations
• 8.11. Market Attractiveness Analysis

9. South Asia & Oceania Growth Factors Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
  • 9.2.1. By Country
  • 9.2.2. By Product
  • 9.2.3. By Grade
  • 9.2.4. By Application
  • 9.2.5. By Expression Host System
  • 9.2.6. By Mode of Action
  • 9.2.7. By Species Origin
  • 9.2.8. By End User
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2023 - 2031
  • 9.4.1. Transforming Growth Factors (TGF)
    • 9.4.1.1. Activin
    • 9.4.1.2. Bone Morphogenetic Proteins (BMPs)
    • 9.4.1.3. TGF-beta Proteins
  • 9.4.2. Epidermal Growth Factors (EGFs)
  • 9.4.3. Platelet-Derived Growth Factors (PDGFs)
  • 9.4.4. Fibroblast Growth Factors (FGFs)
  • 9.4.5. Insulin-like Growth Factors (IGFs)
  • 9.4.6. Vascular Endothelial Growth Factors (VEGFs)
  • 9.4.7. Hepatocyte Growth Factors (HGFs)
  • 9.4.8. Tumor Necrosis Factors (TNFs)
  • 9.4.9. Interleukins
  • 9.4.10. Others
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Grade, 2023 - 2031
  • 9.5.1. GMP Grade
  • 9.5.2. NON-GMP Grade
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2023 - 2031
  • 9.6.1. Oncology
  • 9.6.2. Hematology
  • 9.6.3. Wound Healing
  • 9.6.4. Dermatology
  • 9.6.5. Cardiovascular Disease & Diabetes
  • 9.6.6. Cell Therapy & EX-vivo Manufacturing
  • 9.6.7. Others
• 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By Expression Host System, 2023 - 2031
  • 9.7.1. Animal-Derived Growth Factors
  • 9.7.2. Recombinant Growth Factors
• 9.8. Current Market Size (US$ Bn) Analysis and Forecast, By Mode of Action, 2023 - 2031
  • 9.8.1. Angiogenic Growth Factors
  • 9.8.2. Anti-Apoptotic Growth Factors
  • 9.8.3. Mitogenic Growth Factors
• 9.9. Current Market Size (US$ Bn) Analysis and Forecast, By Species Origin, 2023 - 2031
  • 9.9.1. Human
  • 9.9.2. Pig
  • 9.9.3. Mouse
  • 9.9.4. Rat
  • 9.9.5. Others
• 9.10. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2023 - 2031
  • 9.10.1. Pharmaceutical and Biotechnology Companies
  • 9.10.2. Research Centers & Academic Institutes
  • 9.10.3. Contract Research Organizations
• 9.11. Market Attractiveness Analysis

10. Latin America Growth Factors Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
  • 10.2.1. By Country
  • 10.2.2. By Product
  • 10.2.3. By Grade
  • 10.2.4. By Application
  • 10.2.5. By Expression Host System
  • 10.2.6. By Mode of Action
  • 10.2.7. By Species Origin
  • 10.2.8. By End User
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2023 - 2031
  • 10.4.1. Transforming Growth Factors (TGF)
    • 10.4.1.1. Activin
    • 10.4.1.2. Bone Morphogenetic Proteins (BMPs)
    • 10.4.1.3. TGF-beta Proteins
  • 10.4.2. Epidermal Growth Factors (EGFs)
  • 10.4.3. Platelet-Derived Growth Factors (PDGFs)
  • 10.4.4. Fibroblast Growth Factors (FGFs)
  • 10.4.5. Insulin-like Growth Factors (IGFs)
  • 10.4.6. Vascular Endothelial Growth Factors (VEGFs)
  • 10.4.7. Hepatocyte Growth Factors (HGFs)
  • 10.4.8. Tumor Necrosis Factors (TNFs)
  • 10.4.9. Interleukins
  • 10.4.10. Others
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Grade, 2023 - 2031
  • 10.5.1. GMP Grade
  • 10.5.2. NON-GMP Grade
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2023 - 2031
  • 10.6.1. Oncology
  • 10.6.2. Hematology
  • 10.6.3. Wound Healing
  • 10.6.4. Dermatology
  • 10.6.5. Cardiovascular Disease & Diabetes
  • 10.6.6. Cell Therapy & EX-vivo Manufacturing
  • 10.6.7. Others
• 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Expression Host System, 2023 - 2031
  • 10.7.1. Animal-Derived Growth Factors
  • 10.7.2. Recombinant Growth Factors
• 10.8. Current Market Size (US$ Bn) Analysis and Forecast, By Mode of Action, 2023 - 2031
  • 10.8.1. Angiogenic Growth Factors
  • 10.8.2. Anti-Apoptotic Growth Factors
  • 10.8.3. Mitogenic Growth Factors
• 10.9. Current Market Size (US$ Bn) Analysis and Forecast, By Species Origin, 2023 - 2031
  • 10.9.1. Human
  • 10.9.2. Pig
  • 10.9.3. Mouse
  • 10.9.4. Rat
  • 10.9.5. Others
• 10.10. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2023 - 2031
  • 10.10.1. Pharmaceutical and Biotechnology Companies
  • 10.10.2. Research Centers & Academic Institutes
  • 10.10.3. Contract Research Organizations
• 10.11. Market Attractiveness Analysis

11. Middle East & Africa Growth Factors Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
  • 11.2.1. By Country
  • 11.2.2. By Product
  • 11.2.3. By Grade
  • 11.2.4. By Application
  • 11.2.5. By Expression Host System
  • 11.2.6. By Mode of Action
  • 11.2.7. By Species Origin
  • 11.2.8. By End User
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2023 - 2031
  • 11.4.1. Transforming Growth Factors (TGF)
    • 11.4.1.1. Activin
    • 11.4.1.2. Bone Morphogenetic Proteins (BMPs)
    • 11.4.1.3. TGF-beta Proteins
  • 11.4.2. Epidermal Growth Factors (EGFs)
  • 11.4.3. Platelet-Derived Growth Factors (PDGFs)
  • 11.4.4. Fibroblast Growth Factors (FGFs)
  • 11.4.5. Insulin-like Growth Factors (IGFs)
  • 11.4.6. Vascular Endothelial Growth Factors (VEGFs)
  • 11.4.7. Hepatocyte Growth Factors (HGFs)
  • 11.4.8. Tumor Necrosis Factors (TNFs)
  • 11.4.9. Interleukins
  • 11.4.10. Others
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Grade, 2023 - 2031
  • 11.5.1. GMP Grade
  • 11.5.2. NON-GMP Grade
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2023 - 2031
  • 11.6.1. Oncology
  • 11.6.2. Hematology
  • 11.6.3. Wound Healing
  • 11.6.4. Dermatology
  • 11.6.5. Cardiovascular Disease & Diabetes
  • 11.6.6. Cell Therapy & EX-vivo Manufacturing
  • 11.6.7. Others
• 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By Expression Host System, 2023 - 2031
  • 11.7.1. Animal-Derived Growth Factors
  • 11.7.2. Recombinant Growth Factors
• 11.8. Current Market Size (US$ Bn) Analysis and Forecast, By Mode of Action, 2023 - 2031
  • 11.8.1. Angiogenic Growth Factors
  • 11.8.2. Anti-Apoptotic Growth Factors
  • 11.8.3. Mitogenic Growth Factors
• 11.9. Current Market Size (US$ Bn) Analysis and Forecast, By Species Origin, 2023 - 2031
  • 11.9.1. Human
  • 11.9.2. Pig
  • 11.9.3. Mouse
  • 11.9.4. Rat
  • 11.9.5. Others
• 11.10. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2023 - 2031
  • 11.10.1. Pharmaceutical and Biotechnology Companies
  • 11.10.2. Research Centers & Academic Institutes
  • 11.10.3. Contract Research Organizations
• 11.11. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Thermo Fisher Scientific, Inc.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Merck KGaA
  • 12.3.3. Bio-Rad Laboratories, Inc.
  • 12.3.4. Lonza Group AG
  • 12.3.5. F. Hoffmann-La Roche Ltd.
  • 12.3.6. Sartorius CellGenix GmbH
  • 12.3.7. Bio-Techne Corporation
  • 12.3.8. GenScript
  • 12.3.9. Miltenyi Biotec.
  • 12.3.10. Abcam PLC
  • 12.3.11. Sino Biological Inc.
  • 12.3.12. Cell Signaling Technology, Inc.
  • 12.3.13. ACROBiosystems
  • 12.3.14. Becton, Dickinson, and Company
  • 12.3.15. Creative Bioarray
  • 12.3.16. Applied Biological Materials (abm) Inc.
  • 12.3.17. GE Healthcare
  • 12.3.18. Meridian Bioscience Inc.
  • 12.3.19. Repligen Corporation
  • 12.3.20. Aviva Systems Biology Corporation (GenWay Biotech)
  • 12.3.21. Leadgene Biomedical, Inc.
  • 12.3.22. Boster Bio
  • 12.3.23. Prospec-Tany Technogene Ltd.
  • 12.3.24. Proteintech Group, Inc.
  • 12.3.25. AJINOMOTO CO.,INC
  • 12.3.26. STEMCELL Technologies
  • 12.3.27. Akron Biotech
  • 12.3.28. PeproTech Inc.

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations